

VIA EFS Web
Date of Filing: November 23, 2009

Attorney Docket No. CST-209
PAIR Customer No.: 31012

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Polakiewicz *et al.*
ASSIGNEE: CELL SIGNALING TECHNOLOGY, INC.
SERIAL NUMBER: 10/694,874 EXAMINER: Ewoldt, Gerald R
FILING DATE: November 13, 2003 ART UNIT: 1644
FOR: ANTIBODIES SPECIFIC FOR PHOSPHORYLATED INSULIN RECEPTOR SUBSTRATE-1/2
(SER1101/SER1149) AND USES THEREOF

Mail Stop: Amendment
Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313

**AMENDMENT AND RESPONSE
(37 C.F.R. §§1.111, 1.121)**

This paper is filed in response to the Office Action dated October 13, 2009 (hereinafter the "Action") that has issued in connection with the above-identified patent application (hereinafter "Application"). Applicant previously submitted a response to the Action on November 19, 2009 that may not have been fully compliant with the requirements of 37 C.F.R. §1.121. Accordingly, Applicant is re-responding to the Action herein. A response to the Action is due on or before December 13, 2009.

The Action states that the specification of the Application is not compliant with 37 C.F.R. § 1.821 through 1.825 because the amino acid sequences set forth in Figure 8 are not identified by a SEQ ID NO. Accordingly, Applicant submits herewith an amendment to the specification and the drawings that properly identifies the sequences in Figure 8 by SEQ ID NO's.

Amendments to the Specification: page 2 of this paper

Amendments to the Drawings: page 3 of this paper

Remarks: page 4 of this paper.

This Amendment complies with the requirements of 37 C.F.R. §1.121.